JOHN SULLIVAN: Open Payments
NPI 1851597389 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,336 in 106 payments from 10 companies in 2025. Trend: 2023 $1,459 · 2024 $4,508 · 2025 $4,336
Food & beverage: $2,314Consulting: $1,840Education: $183
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $2,114 |
| Vanda Pharmaceuticals Inc. | 16 | $461 |
| Teva Pharmaceuticals USA, Inc. | 10 | $396 |
| Neurocrine BioSciences, Inc. | 15 | $344 |
| Otsuka America Pharmaceutical, Inc. | 15 | $333 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $247 |
| ABBVIE INC. | 7 | $181 |
| Alkermes, Inc. | 10 | $160 |
| Lundbeck LLC | 4 | $81 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: FANAPT, REXULTI, INGREZZA, COBENFY, CAPLYTA, UZEDY, ARISTADA, VRAYLAR.
Industry payments across CA — which companies pay providers there.
